S/*0*
CINV
P /*0 ondansetron ( / 0
/*0///+0/+0/00
+'+0,80/)-=7S5AB5VV@:&00
04?8mgIm
%
ondansetron'?)/,mgondansetron
* * *- )% = + V4,8 mgIkg ;#;<"$; '?) /
//*'/***-)%=&U00/
?, mg * ondansetron %'00) ( 5 0& S+0
(00/0*0000*,Y
X78mgIm
%
ondansetron'?)/,mgondansetron**:/,X7V4,8mgIkg
'?)///*'/**:& +'0/+
*0 '0 + 0 '0 )0) (= L ) )
&
U004+'+4(*0//*'/07S5AB,VV5:
,5-0/)l=4L+0(00/0*0
001
vl5X)=4*ondansetron0(+0/'?)*08mgIm
%
T%
),mgLT*0**&
vlX)=4*ondansetron0(+0/**0-mgT%Q,mg
LT*0**/000&
U0 0 / ? , mg ondansetron '
00)(%0& +'0/+*0'0+0'0
)0)(=L))&
P/*0ondansetronl80/@),-0=+0/
+40(//+0/7S5A,V5%V:&]?5
*)V&8mgIkgondansetron'?)40(5V0L00
0/ ,/-=*0=0*0& S+0
(0008@X)=&
R 0 +4 0 (//+ 0 / 7S5A%5Y:4 +0/ 0
/*0'?*0 ondansetron ) V&8 mgIkg4/0
****;#;<"$;),mg(0/Z%=/-
mg (0/O%=7/**= nw%-:&S+0(0
00,%X)=&
PONV
P /*0 + *0 ondansetron 0 *0N0 0 (0/+
/4+0/00+'+4(*0//*
'/0@lV0/)%,0=70/00N0O,,
?)4 ? O 5 kg:& ^ (0/ ?0
///+(/+?0(/+0/ASAstatus[III&U+
*0ondansetron0(+0/8*0()(+00&M*
) *) 0 * / 0
/0%,)0*/007ITT:4+((
? //* '/ 0 / ? ondansetron 7%-X
X4pZV&VVV:&
M'(*//*'/4L,@Y
4//0/'7%)%=:4?+0(/+
0&R0(+0//*'?*